Blockade Of Il 23 Prevents Development Of Psoriasis Microscopic View Download Scientific Diagram
Two approved and two pending antiIL 23 drugs offer an opportunity for moderate to severe psoriasis patients to regain their lives, according to researchers presenting at the 18 Fall Clinical Dermatology Conference MIAMI BEACH, Fla — Antiinterleukin23 agents tildrakizumab, guselkumab, risankizumab and mirikizumab are effective in treating patients with psoriasis, with one of the longest remission
